Publications

Author

Article

Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer’s disease

I Koychev, J Lawson, T Chessell, C Mackay, R Gunn, B Sahakian, J B Rowe, A J Thomas, L Rochester, D Chan, B Tom P Malhotra, C Ballard, I Chessell, C W Ritchie, V Raymont, I Leroi, I Lengyel, M Murray, D L Thomas, J Gallacher, S Lovestone, 23 March 2019

Koychev I, Lawson J, Chessell T, et alDeep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer’s diseaseBMJ Open 2019;9:e024498.

Article

The Validity of the Alcohol-Use-Disorder-Identification-Test and a Novel Proxy Test in the Assessment of Alcohol Consumption in the Cognitively Impaired Elderly

A Patel, L Gibbor, R Douch, M Westead, E Cahill, C Kouimtsidis, D Wilson, S Gregory, M Manalo, P Mandalia, S Deriziotis, S Kaya, K Wells, V Raymont, 17 May 2018

Raymont V et al (2018). The Validity of the Alcohol-Use-Disorder-Identification-Test and a novel proxy test in the Assessment of Alcohol Consumption in the Cognitively Impaired Elderly.J Addict Res; 2(1);1-8.

Article

A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocol

V Raymont, P Passmore, C Ballard, A J Thomas, C Greenham, L Murphy, 18 July 2016

Greenan C, Murphy L, Yu LM, et al. A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocol. Trials. 2016;17(1):324.

Article

A phase II trial of tideglusib in Alzheimer's disease

S Lovestone, V Raymont, M Boada, B Dubois, 3 March 2015

Lovestone S, Boada M, Dubois B, et al. A phase II trial of tideglusib in Alzheimer's disease. J Alzheimers Dis. 2015;45(1):75-88.

Article

Decision-making capacity for treatment in psychiatric and medical in-patients: cross-sectional, comparative study

G S Owen, G Szmukler, A S David, V Raymont, M Hotopf, 1 December 2013

Owen GS, Szmukler G, Richardson G, et al. Decision-making capacity for treatment in psychiatric and medical in-patients: cross-sectional, comparative study. Br J Psychiatry. 2013;203(6):461-467.

Article

Characterization of [11C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans

D F Wong, S Ostrowitzki, Y Zhou, V Raymont, A Kumar, J R. Brasic, J Hilton, R F Dannals, 1 July 2013

Wong DF, Ostrowitzki S, Zhou Y, et al. Characterization of [11C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans. Neuroimage. 2013;75:282-290.

Article

Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography

P B Rosenberg, D F Wong, J R. Brasic, Y Zhou, V Raymont, A Kumar, R F Dannals, M J Pontecorvo, D M Skovronsky, C Lyketsos, 1 March 2013

Rosenberg PB, Wong DF, Edell SL, et al. Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography. Am J Geriatr Psychiatry. 2013;21(3):272-278.

Article

Glycine Transporter Type 1 Occupancy by Bitopertin: a Positron Emission Tomography Study in Healthy Volunteers

M Martin-Facklam, F Pizzagalli, Y Zhou, S Ostrowitzki, V Raymont, J R. Brasic, R F Dannals, D F Wong, 1 February 2013

Martin-Facklam M, Pizzagalli F, Zhou Y, et al. Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteers. Neuropsychopharmacology. 2013;38(3):504-512.

Article

Positron emission tomography experience with 2-[¹⁸F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[¹⁸F]FA) in the living human brain of smokers with paranoid schizophrenia

J R. Brasic, N Cascella, A Kumar, Y Zhou, J Hilton, V Raymont, A G Horti, D F Wong, 29 December 2011

Brašić JR, Cascella N, Kumar A, et al. Positron emission tomography experience with 2-[¹⁸F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[¹⁸F]FA) in the living human brain of smokers with paranoid schizophrenia. Synapse. 2012;66(4):352-368

Article

In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18)

D F Wong, P B Rosenberg, Y Zhou, A Kumar, V Raymont, H T Ravert, R F Dannals, A Nandi, J R. Brasic, W Ye, J Hilton, C Lyketsos, H F Kung, A D Joshi, D M Skovronsky, M J Pontecorvo, 1 June 2010

Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45. J Nucl Med. 2010;51(6):913-920

Article

Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR

V Raymont, D F Wong, A G Horti, J R. Brasic, W Ye, R F Dannals, H Kuwabara, 18 April 2010

Wong DF, Kuwabara H, Horti AG, et al. Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. Neuroimage. 2010;52(4):1505-1513

Article

Demographic, structural and genetic predictors of late cognitive decline after penetrating head injury

V Raymont, A Greathouse, K Reding, R Lipsky, A Salazar, J Grafman, 19 December 2008

Vanessa Raymont, Amanda Greathouse, Katherine Reding, Robert Lipsky, Andres Salazar, Jordan Grafman, Demographic, structural and genetic predictors of late cognitive decline after penetrating head injury, Brain, Vol 131, Issue 2, Feb 2008, Pg 543-558

Article

Focal brain damage protects against post-traumatic stress disorder in combat veterans

M Koenigs, E D Huey, V Raymont, B Cheon, J Solomon, E M Wassermann, J Grafman, 23 December 2007

Koenigs, M., Huey, E., Raymont, V. et al. Focal brain damage protects against post-traumatic stress disorder in combat veterans. Nat Neurosci 11, 232–237 (2008)

Article

The inter-rater reliability of mental capacity assessments

V Raymont, A Buchanan, A S David, P Hayward, S Wessely, M Hotopf, 1 March 2007

Raymont V, Buchanan A, David AS, Hayward P, Wessely S, Hotopf M. The inter-rater reliability of mental capacity assessments. Int J Law Psychiatry. 2007;30(2):112-117

Article

Prevalence of mental incapacity in medical inpatients and associated risk factors: cross-sectional study

V Raymont, W Bingley, A Buchanan, A S David, P Hayward, S Wessely, M Hotopf, 16 October 2004

Raymont V, Bingley W, Buchanan A, et al. Prevalence of mental incapacity in medical inpatients and associated risk factors: cross-sectional study. Lancet. 2004;364(9443):1421-1427

Article

The Maudsley bipolar disorder project Clinical characteristics of bipolar disorder I in a Catchment area treatment sample

V Raymont, D Bettany, S Frangou, 1 March 2003

Raymont, V., Bettany, D., & Frangou, S. (2003). The Maudsley bipolar disorder project Clinical characteristics of bipolar disorder I in a Catchment area treatment sample. European Psychiatry, 18(1), 13-17.

Article

The Maudsley Bipolar Disorder Project: The effect of medication, family history and duration of illness on IQ and memory in bipolar I disorder.

V Raymont, S Donaldson, L H Goldstein, S Frangou, 1 January 2003

Donaldson, S., Goldstein, L. H., Landau, S., Raymont, V., & Frangou, S. (2003). The Maudsley Bipolar Disorder Project: The effect of medication, family history and duration of illness on IQ and memory in bipolar I disorder. The Journal of Clinical Psychia

Article

The Maudsley bipolar disorder project. A survey of psychotropic prescribing patterns in bipolar I disorder

V Raymont, D Bettany, S Frangou, 11 December 2002

Frangou, S., Raymont, V. and Bettany, D. (2002), The Maudsley bipolar disorder project. A survey of psychotropic prescribing patterns in bipolar I disorder. Bipolar Disorders, 4: 378-385. doi:10.1034/j.1399-5618.2002.01223.x